Background Molecular tests are being used increasingly as an auxiliary diagnostic tool so
as to avoid a diagnostic surgery approach for cytologically indeterminate thyroid nodules …

Thyroid nodules are extremely common and can be detected by sensitive imaging in more
than 60% of the general population. They are often identified in patients without symptoms …

Importance Approximately 20% of thyroid nodules display indeterminate cytology. Molecular
testing can refine the risk of malignancy and reduce the need for diagnostic …

Thyroid cancer is the most common endocrine malignancy with an estimated 43,800 new
cases to be diagnosed in 2022 and representing the 7th most common cancer in women …

Context Broad genomic analyses among thyroid histologies have been described from
relatively small cohorts. Objective Investigate the molecular findings across a large, real …

Molecular testing contributes to improving the diagnosis of indeterminate thyroid nodules
(ITNs). ThyroidPrint® is a ten-gene classifier aimed to rule out malignancy in ITN. Post …

Abstract Context The Afirma® GSC aids in risk stratifying indeterminate thyroid nodule
cytology (ITN). The 2018 GSC validation study (VS) reported a sensitivity (SN) of 91 …

Context Molecular tests have improved the accuracy of preoperative diagnosis of
indeterminate thyroid nodules. The Afirma Gene Sequencing Classifier (GSC) was …

Thyroid nodules are common in the adult population where a majority are benign and only
4.0% to 6.5% are malignant. Fine needle aspiration (FNA) is a key method used in the early …

Cytologically indeterminate thyroid nodules remain a diagnostic and clinical challenge, and
molecular testing has been advocated and advanced as a diagnostic modality to help guide …